Free tool
FAERS Monitor: Fml
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 016851 or its brand name (Fml, Fluorometholone). Reports on generic versions are filed under their own applications.
Reports
3,120
Serious
1,612
52% of reports
Hospitalization
790
Death reported
316
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- treatment failure371
- drug ineffective232
- eye pain224
- off label use217
- fatigue212
- diarrhoea180
- headache177
- dyspnoea173
- arthralgia167
- eye irritation158
- condition aggravated153
- dizziness146
- pruritus146
- nausea145
- anxiety142
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 11 |
| 2005 | 6 |
| 2006 | 14 |
| 2007 | 10 |
| 2008 | 13 |
| 2009 | 21 |
| 2010 | 43 |
| 2011 | 37 |
| 2012 | 63 |
| 2013 | 52 |
| 2014 | 62 |
| 2015 | 85 |
| 2016 | 176 |
| 2017 | 141 |
| 2018 | 147 |
| 2019 | 168 |
| 2020 | 453 |
| 2021 | 215 |
| 2022 | 234 |
| 2023 | 247 |
| 2024 | 297 |
| 2025 | 353 |
| 2026 | 272 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,039 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| treatment failureSignal | 371 | 30.3 | 27.6 | 10,484 |
| eye painSignal | 224 | 26.9 | 23.7 | 5,546 |
| eye irritationSignal | 158 | 18.6 | 15.9 | 2,606 |
| condition aggravatedSignal | 153 | 3.4 | 2.9 | 260 |
| anxietySignal | 142 | 3.4 | 2.9 | 237 |
| arthralgiaSignal | 167 | 2.7 | 2.3 | 182 |
| pruritusSignal | 146 | 2.6 | 2.2 | 140 |
| dyspnoeaSignal | 173 | 2.1 | 1.8 | 96 |
| dizziness | 146 | 2.0 | 1.7 | 71 |
| headache | 177 | 1.9 | 1.6 | 77 |
| diarrhoea | 180 | 1.9 | 1.6 | 76 |
| fatigue | 212 | 1.8 | 1.6 | 83 |
| off label use | 217 | 1.7 | 1.5 | 60 |
| nausea | 145 | 1.2 | 1.1 | 6 |
| drug ineffective | 232 | 1.2 | 1.0 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.